Laryngopharyngeal reflux disease in a series of Kashmiri patients at a tertiary care setting


  • Syed Waseem Abbas Department of Health, Govt Medical College Srinagar, Jammu and Kashmir, India
  • Majid Ul Islam Masoodi Department of Otorhinolaryngology, Govt Medical College Srinagar, Jammu and Kashmir, India
  • Viqar Khursheed Mir Department of Otorhinolaryngology, Govt Medical College Srinagar, Jammu and Kashmir, India



Laryngophyrngeal, Esophageal, Reflux, Proton pump inhibitor


Background: Laryngopharyngeal reflux (LPR) is retrograde flow of gastric contents into the larynx, oropharynx and/ or nasopharynx. LPR causes respiratory symptoms such as cough and wheezing and is often associated with head and neck complaints such as dysphoniaglobus pharyngus, and dysphagia.

Methods: this is an observational study conducted over a period of 18 months at ENT OPD, GMC Srinagar. All patients aged 15 years and above who presented with clinical diagnosis of LPR, not taking any treatment were included. Demographic, dietary and RSI data were obtained by mean of a questionnaire. The 130 patients were recruited and given uniform treatment including antacids and PPIs and lifestyle modification. Routine follow up and assessment with repeat administration of the questionnaire and FOL was arranged for all patients at a period of 4 weeks from the initial assessment.

Results: The 130 patients were included. 100 were females (76.9%). The mean age was 41.1. The mean RSI and RFS were 9.2 (SD 2.9) and 6.9 (SD 2.5) respectively. Highest observed were troublesome coughs (0.25) and breathing difficulties (0.37). Highest observed RFS were erythema (2.03), ventricular obliteration (1.54) and posterior commissure hypertrophy (1.18) and lowest observed was vocal cord granuloma (0). 27.7% of patients had associated dental erosions and 12.3% had symptoms suggestive of sinusitis.

Conclusions: LPR in the study population was more common in females. Lack of association between RSI and RFR is note-worthy. Dietary modifications and pharmacological management are associated with statistically significant RSI and RFS improvement.


Kahrilas PJ. Maximizing outcome of extra-esophageal reflux disease. Am J Manag Care. 2000;6(16):S876-82.

Cazzola M, Segreti A, Calzetta L, Rogliani P. Comorbidities of asthma: current knowledge and future research needs. Current Opinion Pulmonary Med. 2013;19(1):36-41.

Ford CN. Evaluation and management of laryngopharyngeal reflux. JAMA. 2005;1534-40.

Nunes HS, Pinto JA, Zavanela AR, Cavallini AF, Freitas GS, Garcia FE. Comparison between the reflux finding score and the reflux symptom index in the practice of otorhinolaryngology. Int Arch Otorhinolaryngol. 2016;20(3):218-21.

El-Serag HB, Lee P, Buchner A, Inadomi JM, Gavin M, McCarthy DM. Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial. Am J Gastroenterol. 2001;96:979-83.

Eherer AJ, Habermann W, Hammer HF, Kiesler K, Friedrich G, Krejs GJ. Effect of pantoprazole on the course of reflux-associated laryngitis: a placebo controlled double-blind crossover study. Scand J Gastroenterol. 2003;38:462-7.

Steward DL, Wilson KM, Kelly DH, Patil MS, Schwartzbauer HR, Long JD et al. Proton pump inhibitor therapy for chronic laryngopharyngitis: a randomized placebo-control trial. Otolaryngol Head Neck Surg. 2004;131:342-50.

Vaezi M, Richter J, Stasney SR, Spiegel JR, Iannuzzi RA, Crawley JA et al. Treatment of chronic posterior laryngitis with esomeprazole. Laryngoscope 2006;116:254-60.

Kamel PL, Hanson D, Kahrilas PJ. Omeprazole for the treatment of posteriorlaryngitis. Am J Med. 1994;96:321-6.

Del Gaudio JM, Waring JP. Empiric esomeprazole in the treatment of laryngopharyngeal reflux. Laryngoscope. 2003;113:598-601.






Original Research Articles